Pfizer Looking To Tap Into Asia’s Emerging Oncology Market
This article was originally published in PharmAsia News
Executive Summary
Looking to increase global market share, Pfizer has established a business unit devoted to oncology within its worldwide pharmaceutical group, in part, to strengthen research investment on cancers common in Asia, including liver, esophagus and nasopharynx
You may also be interested in...
Pfizer Restructures for a More Flexible Future
In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets. These units join Pfizer's oncology and mature products businesses.
Pharma Business Structure, M&As Evolving To Create Smaller Cross-Functional Units
TOKYO - Strategies for mergers and acquisitions in the global pharmaceutical market are changing from marriages of equals to alliances and buyouts with biotechs, which often create cross-functional smaller units within big pharmas, said Hiroshi Nakamura, professor at the Keio University Business School
Pharma Business Structure, M&As Evolving To Create Smaller Cross-Functional Units
TOKYO - Strategies for mergers and acquisitions in the global pharmaceutical market are changing from marriages of equals to alliances and buyouts with biotechs, which often create cross-functional smaller units within big pharmas, said Hiroshi Nakamura, professor at the Keio University Business School